Clinical trials: First Line Treatment
Diffuse Large B-Cell Lymphoma
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
- Trial name
- NCT00355199
- Testing
- Rituximab-HDS, Rituximab-CHOP
- Where
- 16 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Gruppo Italiano Terapie Innovative nei Linfomi
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK…
- Trial name
- NCT03771157
- Testing
- Shingrix vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Rochester
Breast Cancer
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin.
- Trial name
- NCT00093145
- Testing
- Albumin-bound paclitaxel, Carboplatin, Herceptin®
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- Celgene
Psoriasis Vulgaris
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one…
- Trial name
- NCT02317627
- Testing
- KD025
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kadmon Corporation, LLC
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without…
- Trial name
- NCT01480674
- Testing
- Trastuzumab
- Where
- 78 sites in France
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Head and Neck Carcinoma, Recurrent or Metastatic Disease
Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
PURPOSE: Cetuximab with platinum and 5FU is now the standard combination as first-line treatment in patients with metastatic or recurrent Head and Neck squamous cell carcinomas.
- Trial name
- TPEx (NCT01289522)
- Testing
- cetuximab IV, Biopsies
- Where
- 14 sites in Belgium, France
- Volunteers
- 54 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Synovial Sarcoma, Cancer
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
- Conditions
- Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma
- Trial name
- NCT03520959
- Testing
- LV305, G305
- Where
- 29 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Mesothelioma
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
The purpose of this research study was to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT00604461
- Testing
- Carboplatin, Bevacizumab and Pemetrexed
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
- Trial name
- BOLERO-1 (NCT00876395)
- Testing
- Everolimus, Trastuzumab, Paclitaxel
- Where
- 140 sites in United States, Argentina and 26 more
- Volunteers
- 719 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Bladder Neoplasms
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With…
- Trial name
- BAYOU (NCT03459846)
- Testing
- Durvalumab, Olaparib
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Carcinoma, Small Cell
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC.
- Trial name
- NCT00305942
- Testing
- Topotecan, carboplatin
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- SCRI Development Innovations, LLC
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination…
- Trial name
- NCT02589496
- Testing
- pembrolizumab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Breast Cancer
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
The goals of this clinical research study are to learn the tolerable and effective doses of the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex (fulvestrant) to patients with hormone…
- Trial name
- NCT00903006
- Testing
- Fulvestrant, MK-0646, Dasatinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT00451906
- Testing
- Platinum-based chemotherapy, Bevacizumab [Avastin]
- Where
- 369 sites in Argentina, Australia and 38 more
- Volunteers
- 2,252 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast Neoplasms
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary…
- Trial name
- NCT01684215
- Testing
- PD-0332991, letrozole
- Where
- 16 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Ovarian Cancer
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients.
- Trial name
- MIMOSA (NCT00418574)
- Testing
- Abagovomab
- Where
- 150 sites in United States, Belgium and 7 more
- Volunteers
- 888 people
- Sponsor
- Menarini Group
Colorectal Cancer
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer.
- Trial name
- NCT01555762
- Where
- 166 sites in France
- Volunteers
- 402 people
- Sponsor
- Hoffmann-La Roche
Primary Open-angle Glaucoma
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure…
- Trial name
- NCT03365778
- Testing
- Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Wills Eye